Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

WuXi XDC and Boostimmune sign MoU for integrated services

Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials

Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.

DualityBio collaborates with BioNTech to accelerate development of differentiated antibody-drug conjugate therapeutics

WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.

Bridgewest Group launches new sterile injectable CDMO NovaCina

GeneQuantum and WuXi XDC enter into strategic cooperation to empower innovative bioconjugates development

USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility

The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue

Aragen to operationalize Hyderabad formulation manufacturing facility by Jan 2023

The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting

WuXi STA opens a new sterile lipid nanoparticle formulation facility

This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform